Isomab Ltd. has nominated ISM-001 as a development candidate for peripheral arterial disease. ISM-001 is a potential first-in-class therapeutic antibody designed to neutralize VEGF-A165b, the anti-angiogenic VEGF-A splice isoform that acts as a brake on development of new blood vessels leading to chronic limb threatening ischemia.
Mediar Therapeutics Inc. has announced the nomination of two first-in-class monoclonal antibody clinical candidates for fibrosis. The first, MTX-463, is designed to neutralize WISP-1 signaling. The second candidate, MTX-474, is designed to neutralize EphrinB2 signaling.
As several key revenue-driving products fall off patent in coming years, pharmaceutical companies are increasingly focused on mechanisms by which they can draw innovation to them. What launched as the Partner of Choice organization, for example, has now become the newly named Pfizer Ignite model – an end-to-end engine designed to bring innovation to the pharmaceutical company in return for services.
